Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716912 | 0.90 | KDM4E (0.57) | TRPV1POLBKDM4EMAPTRAB9A | |
| SCHEMBL6716963 | 0.89 | RAB9A (0.59) | POLBKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL6719403 | 0.86 | ALDH1A1 (0.46) | POLBKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL6713932 | 0.86 | KDM4E (0.46) | KDM4EMAPTRAB9ANPC1MEN1 | |
| SCHEMBL6727005 | 0.84 | MAPT (0.50) | KDM4EMAPTRAB9ANPC1MEN1 | |
| SCHEMBL6717589 | 0.83 | MEN1 (0.48) | POLBMAPTRAB9ANPC1MEN1 | |
| SCHEMBL6723214 | 0.78 | ALDH1A1 (0.52) | POLBKDM4EMAPTRAB9ANPC1 | |
| SCHEMBL6715734 | 0.78 | RAB9A (0.54) | TRPV1POLBKDM4EMAPTRAB9A | |
| SCHEMBL6715691 | 0.76 | MAPT (0.54) | POLBMAPTRAB9ANPC1MEN1 | |
| SCHEMBL6713823 | 0.75 | IMPDH2 (0.47) | POLBMAPTRAB9ANPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | TRPV1 1558/4885POLB 4182/4885KDM4E 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.